文献速递腹部技术与安全MR

利用钆塞酸二钠增强MRI肝细胞期相对肿瘤强化预测结直肠癌肝转移的化疗反应

Predicting chemotherapeutic response for colorectal liver metastases using relative tumor enhancement of gadoxetic acid disodium-enhanced magnetic resonance imaging.
PubMed 文献 · Abdom Radiol (NY) · 2018-01-01

回顾性纳入26例无化疗史的结直肠癌肝转移患者,化疗前行钆塞酸二钠增强MRI并测量肝细胞期相对肿瘤强化(RTE)。RECIST 1.1评估应答,应答者15例、非应答者11例,应答者预处理RTE显著高于非应答者(37.2%±10.9% vs 17.9%±10.5%,P=0.0006)。以RTE 24.2%为阈值检出应答者的敏感度93.3%、特异度72.7%、AUC 0.90。

要点

  • 化疗前肝细胞期RTE较高者更可能对化疗应答,阈值24.2%时AUC 0.90。
  • 应答者预处理RTE均值37.2%±10.9%,非应答者17.9%±10.5%(P=0.0006)。
  • 高RTE组较低RTE组进展更慢的趋势,但PFS差异无统计学意义。

核心结论

  • 结直肠癌肝转移的肝细胞期相对肿瘤强化值可能作为预测早期化疗反应的生物标志物。

研究设计与样本

  • 回顾性研究,纳入2011年12月至2017年5月间26例无化疗史的结直肠癌肝转移患者(14男、12女,中位年龄58岁,范围37-82岁),化疗前行钆塞酸二钠增强MRI并测量肝细胞期RTE,以RECIST 1.1评估应答并估算无进展生存期。

关键影像表现/征象

  • 肝细胞期相对肿瘤强化(RTE)在应答者组预处理均值37.2%±10.9%,非应答者组17.9%±10.5%,应答者组显著更高(P=0.0006)。

诊断标准与关键数值

  • 以肝细胞期RTE阈值24.2%检出化疗应答者:敏感度93.3%、特异度72.7%、AUC 0.90。
  • 应答判定采用RECIST 1.1,15例为应答者、11例为非应答者。

临床应用与阅片要点

  • 对无化疗史的结直肠癌肝转移患者,化疗前钆塞酸二钠增强MRI肝细胞期可测量RTE,RTE较高可能提示更易出现化疗应答。
  • 高RTE组与低RTE组PFS差异无统计学意义,但高RTE组进展更慢的趋势(高RTE组PFS未达中位)。

局限性

  • 本研究为回顾性研究。
  • 样本量为26例。
  • 高RTE组与低RTE组PFS差异无统计学意义。
  • 作者结论称RTE「可能」为潜在生物标志物,属初步提示。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: This study aimed to predict the treatment response for colorectal liver metastases (CLM) using relative tumor enhancement (RTE) of the hepatobiliary phase (HBP) for patients with no history of chemotherapy.

MATERIALS AND METHODS: In this retrospective study, we enrolled 26 patients [14 males, 12 females; median age: 58 years (range 37-82 years)] with CLM and no history of chemotherapy between December 2011 and May 2017. Gadoxetic acid-enhanced magnetic resonance imaging was performed before starting chemotherapy and RTE of HBP. The response was evaluated using RECIST ver.1.1, and progression-free survival (PFS) was estimated.

RESULTS: Based on the RECIST ver.1.1, there were 15 responders and 11 non-responders. In the tumor, the mean pretreatment RTE values were significantly higher in the responders group than in the non-responders group (37.2% ± 10.9% vs. 17.9% ± 10.5%, respectively; P = 0.0006). When the threshold values of parameters for detecting responders comprised the RTE value of 24.2% (area under the curve value, 0.90), the sensitivity and specificity were 93.3% and 72.7%, respectively. The median follow-up period for 26 patients was 602 days (range 160-1971 days). Although no significant differences were observed in PFS between the groups, the high RTE group tended to take longer to progress than the low RTE group (PFS of the high RTE group did not reach the median).

CONCLUSION: This study suggests that the RTE value of CLM could be a potential biomarker to predict early treatment response.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Murata S, Matsushima S, Sato Y, et al. Predicting chemotherapeutic response for colorectal liver metastases using relative tumor enhancement of gadoxetic acid disodium-enhanced magnetic resonance imaging. Abdom Radiol (NY). 2018. PMID: 29666951. doi:10.1007/s00261-018-1615-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。